[{"id":"90c16153-3981-40a9-88a1-f2c1a1a280a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04277468","created_at":"2021-01-18T20:46:25.936Z","updated_at":"2025-07-19T13:36:31.619Z","phase":"Phase 1/2","brief_title":"Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1)","source_id_and_acronym":"NCT04277468","lead_sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • DZD3969"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2020-02-20"}]